Are fibrin-related markers useful for the diagnosis of thrombosis?

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 33-38

  Wada, Hideo ^a,d   Sakuragawa, Nobuo ^b,c  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Toyoura Hospital   (Japan)

^d MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

D dimer; Fibrinogen degradation products (FDPs); Soluble fibrin (SF); Thrombosis

Indexed keywords

D DIMER; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT; MARKER;

BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; PRIORITY JOURNAL; REVIEW; RISK; THROMBOSIS;

BIOLOGICAL MARKERS; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; RISK FACTORS; SOLUBILITY; THROMBOSIS; VENOUS THROMBOSIS;

EID: 43149091233     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066021     Document Type: Review

References (32)

1. Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost 2004;2:1256-1260
2. Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004;344:13-21
3. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-463
4. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-1235
5. Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003;349:1247-1255
6. Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995;74:848-852
7. Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Blood 1996;88:2109-2117
8. Kaneko T, Wada H, Onishi K, et al. Cutoff values of D-dimer and FDP in plasma for the diagnosis of thrombosis. Vasc Dis Prevent 2008; (in press)
9. Colman RW, Robby SJ, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1972; 52:679-689
10. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition,, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001;86:1327-1330
11. Nieuwenhuizen W. A reference material for harmonization of D-dimer assays. Thromb Haemost 1997;77:1031-1033
12. Dempfle CE, Zips S, Ergül H, Heene DL. The FACT study group: the fibrin assay comparison trial (FACT). Thromb Haemost 2001;85:671-678
13. Ota S, Wada H, Nobori T, et al. Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer. Am J Hematol 2005;79:274-280
14. Wada H, Kobayashi T, Abe Y, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 2006;4:1253-1258
15. Minamikawa K, Wada H, Wakita Y, et al. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost 1994; 71:192-194
16. Yamada N, Wada H, Nakase T, et al. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. Blood Coagul Fibrinolysis 1995;6:627-633
17. Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998;58:189-194
18. Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993;44:112-116
19. Kline JA, Wells PS. Methodology for a rapid protocol to rule out pulmonary embolism in the emergency department. Am J Emerg Med 2003;42:266-275
20. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999;82: 673-683
21. Asakura H, Suga Y, Yoshida T, et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats. Blood Coagul Fibrinolysis 2003; 14:221-228
22. Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation; the role of fibrinogen-fibrin monomer complex. Thromb Haemost 1976;36:37-48
23. Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 2002;318:25-32
24. Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognize an epitope in the C-terminal region of the fibrinogen α-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res 2007;121:377-385
25. Wada H, Sase T, Matsumoto T, et al. Increased soluble fibrin in plasma from disseminated intravascular coagulation. Clin Appl Thromb Hemost 2003;9:233-240
26. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul Fibrinolysis 1993;4:93-96
27. Sumida Y, Wada H, Fuzii M, et al. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent-daibetes mellitus. Blood Coagul Fibrinol 1977;8: 303-307
28. Nielsen NE, Siegbahn A, Swahn E. Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics. J Intern Med 2000;248:151-158
29. Ieko M, Nakabayashi T, Tarumi T, et al. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis. Clin Chim Acta 2007;386:38-45
30. Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost 1998; 24:293-297
31. Watanabe R, Wada H, Yamamuro M, et al. Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation. Clin Appl Thromb Hemost 2003; 9:71-78
32. Matsumoto T, Wada H, Nobori T, et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2005;11:391-400